Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.

Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page
- Check5 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision: v3.4.3 was added, and Revision: v3.4.2 was removed from the page.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.4.2 was added. The government funding status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a government funding lapse notice and Clinical Center status guidance, and updated the site revision to v3.4.1 (replacing v3.4.0); to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check55 days agoChange DetectedGlossary display has been added, and the label 'Last Update Submitted that Met QC Criteria' appears with updated capitalization. Footer text now shows 'No FEAR Act data' and 'Revision: v3.4.0', replacing the previous wording and version.SummaryDifference0.2%

- Check69 days agoChange DetectedMinor revision label updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.